Parkinson's inhaler trial halted after just 8 patients
NCT ID NCT05979415
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an inhaled form of apomorphine (AZ-009) to quickly treat 'OFF' episodes in people with Parkinson's disease—times when symptoms like stiffness or trouble moving return between regular medication doses. The trial was planned for more participants but was terminated early, with only 8 people enrolled. Because it stopped so early, we don't have enough information to know if the treatment works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Staccato Apomorphine (AZ-009)
What this could lead to
If it works, this could provide a fast-acting treatment to quickly relieve Parkinson's 'OFF' episodes when symptoms return between medication doses.
What could go wrong
This trial was terminated early and enrolled only 8 people, so results are very limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accellacare of Piedmont Healthcare
Statesville, North Carolina, 28265, United States
-
Bradenton Research Center, Inc.
Bradenton, Florida, 34205, United States
-
CenExel iResearch Atlanta (Decatur)
Decatur, Georgia, 30030, United States
-
Cenexel Rocky Mountain Clinical Research
Englewood, Colorado, 80113, United States
-
Holy Cross Health
Fort Lauderdale, Florida, 33308, United States
-
KCA Neurology, (Part of Ki Health Partners, LLC)
Franklin, Tennessee, 37067, United States
-
Lone Star Neurology, (Part of Ki Health Partners, LLC)
Frisco, Texas, 75035, United States
-
Movement Disorders Center of Arizona
Scottsdale, Arizona, 85258, United States
-
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida, 33980, United States
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
-
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, 92708, United States
-
Tuscon Neuroscience Research (M3 Wake Research)
Tucson, Arizona, 85710, United States
-
Visionary Investigators Network
Miami, Florida, 33133, United States